Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy in triple-negative breast cancer.
Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy (Trodelvy) in triple-negative breast cancer (TNBC).
Sacituzumab govitecan, an antibody-drug conjugate, is a standard treatment option for patients with metastatic TNBC. Other breast cancer therapies, such as immunotherapy, can only be administered to a select group of patients with TNBC, Patt says.
As more targeted therapies enter the TNBC paradigm, it will be important to glean a better understanding of which patients will derive the most benefit from sacituzumab govitecan. However, as it stands, sacituzumab govitecan can be used more broadly for patients with TNBC compared with other therapies, Patt concludes.